Related references
Note: Only part of the references are listed.Obesity is associated with improved postoperative overall survival, independent of skeletal muscle mass in lung adenocarcinoma
Ji Hyun Lee et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2022)
Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade
Seong-Keun Yoo et al.
JAMA NETWORK OPEN (2022)
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data
Y. Di Filippo et al.
ANNALS OF ONCOLOGY (2021)
Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: A comprehensive systematic review and meta-analysis
Han-Yu Deng et al.
NUTRITION (2021)
Re-Evaluating the Effects of Obesity on Cancer Immunotherapy Outcomes in Renal Cancer: What Do We Really Know?
Kristine Farag et al.
FRONTIERS IN IMMUNOLOGY (2021)
Editorial: Pathophysiological Interrelationship Between Obesity, Metabolic Diseases, and Cancer
Manuel D. Gahete et al.
FRONTIERS IN ONCOLOGY (2021)
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors
Kazuki Takada et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
Eiki Ichihara et al.
LUNG CANCER (2020)
Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
Mariko Tsukagoshi et al.
MEDICINE (2020)
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer
Ganessan Kichenadasse et al.
JAMA ONCOLOGY (2020)
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
Alessio Cortellini et al.
SCIENTIFIC REPORTS (2020)
Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
Michael P. Chu et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
Benoit Roch et al.
LUNG CANCER (2020)
Impact of body composition on outcomes from anti-PD1+/- anti-CTLA-4 treatment in melanoma
Arissa C. Young et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Yue An et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies
Lin Xia et al.
CANCER MEDICINE (2020)
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Karam Khaddour et al.
FRONTIERS IN ONCOLOGY (2020)
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
Piotr Rutkowski et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer
Paul Johannet et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
Naoya Nishioka et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The prognostic role of obesity is independent of sex in cancer patients treated with immune checkpoint inhibitors: A pooled analysis of 4090 cancer patients
Huilin Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
From cachexia to obesity: the role of host metabolism in cancer immunotherapy
Davide Brocco et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2019)
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
Valentina Magri et al.
CANCER MANAGEMENT AND RESEARCH (2019)
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients
Douglas Donnelly et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Lea Gauci et al.
CLINICAL CANCER RESEARCH (2019)
Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
Takayuki Shiroyama et al.
SCIENTIFIC REPORTS (2019)
Assessment of Computed Tomography (CT)-Defined Muscle and Adipose Tissue Features in Relation to Short-Term Outcomes After Elective Surgery for Colorectal Cancer: A Multicenter Approach
Lisa Martin et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade et al.
LANCET ONCOLOGY (2018)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study
Georg Richtig et al.
PLOS ONE (2018)
The 'obesity paradox' may not be a paradox at all
H. R. Banack et al.
INTERNATIONAL JOURNAL OF OBESITY (2017)
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Laurent Dercle et al.
EUROPEAN JOURNAL OF CANCER (2016)
Body Fatness and Cancer - Viewpoint of the IARC Working Group
Beatrice Lauby-Secretan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Morphomics Predicts Response to Ipilimumab in Patients With Stage IV Melanoma
Michael S. Sabel et al.
JOURNAL OF SURGICAL ONCOLOGY (2015)
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Share Paper
